Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport

FEBS Letters

Volumn 587, Issue 9, 2013, Pages 1271-1274

  Shen, Li ^a   Peng, Hong Chun ^b   Nees, Shannon N ^c   Zhao, Shui Ping ^a   Xu, Dan Yan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CHANGSHA CENTRAL HOSPITAL   (China)

^c Columbia University ^*  (United States)

Author keywords

Atherosclerosis; Low density lipoprotein receptor; PCSK9; Reverse cholesterol transport

Indexed keywords

CHOLESTEROL; KEXIN; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG;

ARTERIAL WALL THICKNESS; ARTICLE; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; INTESTINE ABSORPTION; MACROPHAGE; NONHUMAN; PATHOGENESIS; PCSK9 GENE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; BIOLOGICAL TRANSPORT; CHOLESTEROL; FOAM CELLS; HUMANS; INTESTINAL ABSORPTION; LIVER; MACROPHAGES; MICE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

MUS;

EID: 84876464830     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.02.027     Document Type: Article

References (32)

1. A.B.R. Iryna Voloshyna The ABC transporters in lipid flux and atherosclerosis Prog. Lipid Res. 50 2011 213 224
2. Emil M. deGoma, Rolando L. deGoma, and Daniel J. Rader Beyond high-density lipoprotein cholesterol levels: evaluating high-density lipoprotein function as influenced by novel therapeutic approaches J. Am. Coll. Cardiol. 51 2008 2199 2211
3. N.G. Seidah PCSK9 as a therapeutic target of dyslipidemia Expert Opin. Ther. Targets 13 2009 19 28
4. B. Cariou, C. Le May, and P. Costet Clinical aspects of PCSK9 Atherosclerosis 216 2011 258 265
5. B. Herbert, D. Patel, S.N. Waddington, E.R. Eden, A. McAleenan, X.M. Sun, and A.K. Soutar Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control Arterioscler. Thromb. Vasc. Biol. 30 2010 1333 1339
6. H. Yoshida, and R. Kisugi Mechanisms of LDL oxidation Clin. Chim. Acta 411 2010 1875 1882
7. N. Ferri, G. Tibolla, A. Pirillo, F. Cipollone, A. Mezzetti, S. Pacia, A. Corsini, and A.L. Catapano Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels Atherosclerosis 220 2012 381 386
8. C.Y. Wu, Z.H. Tang, L. Jiang, X.F. Li, Z.S. Jiang, and L.S. Liu PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway Mol. Cell. Biochem. 359 2011 347 358
9. Z.H. Tang, L.S. Liu, and Z.S. Jiang NARC-1/PCSK9 is expressed in atherosclerotic lesion of New Zealand rabbit Chin. J. Arterioscler. 17 2009 439 443
10. L.S. Liu, Y.L. Cheng, and Z.S. Jiang Effects of LDL and oxLDL on expression of PCSK9 and LDLR in THP-1 macrophages Prog. Biochem. Biophys. 35 2008 540 547
11. L.S. Liu, M. Xie, Z.S. Jiang, Q. Yang, L.H. Pan, C.Y. Wu, Z.H. Tang, C.K. Tang, D.H. Wei, and Z. Wang Effects of PCSK9 siRNA on THP-1 derived macrophages apoptosis induced by ox-LDL Prog. Biochem. Biophys. 36 2009 323 330
12. M. Denis, J. Marcinkiewicz, A. Zaid, D. Gauthier, S. Poirier, C. Lazure, N.G. Seidah, and A. Prat Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice Circulation 125 2012 894 901
13. I. Tabas, K.J. Williams, and J. Boren Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 2007 1832 1844
14. J.E. McLaren, D.R. Michael, T.G. Ashlin, and D.P. Ramji Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy Prog. Lipid Res. 50 2011 331 347
15. R.K. Tangirala, M.J. Mol, and D. Steinberg Macrophage oxidative modification of low density lipoprotein occurs independently of its binding to the low density lipoprotein receptor J. Lipid Res. 37 1996 835 843
16. Z.H. Tang, C.Y. Wu, L.S. Liu, and Z.S. Jiang Effects of PCSK9 siRNA on CD36, SR-A1 and SR-B1 expression in THP-1 derived macrophages Acta Univ. Med. Nanjing 05 2010 673 678
17. J. Han, D.P. Hajjar, M. Febbraio, and A.C. Nicholson Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36 J. Biol. Chem. 272 1997 21654 21659
18. X. Zhou, W. He, Z. Huang, A.M. Gotto Jr., D.P. Hajjar, and J. Han Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression. A new SREBP1-dependent mechanism J. Biol. Chem. 283 2008 2129 2138
19. A.V. Khera, and D.J. Rader Future therapeutic directions in reverse cholesterol transport Curr. Atheroscler. Rep. 12 2010 73 81
20. J.L. Goldstein, and M.S. Brown The LDL receptor Arterioscler. Thromb. Vasc. Biol. 29 2009 431 438
21. Z.S. Ji, H.L. Dichek, R.D. Miranda, and R.W. Mahley Heparan sulfate proteoglycans participate in hepatic lipaseand apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins J. Biol. Chem. 272 1997 31285 31292
22. M. Bedi, M. Niesen, and D. Lopez Inhibition of squalene synthase upregulates PCSK9 expression in rat liver Arch. Biochem. Biophys. 470 2008 116 119
23. A.R. Tall, L. Yvan-Charvet, N. Terasaka, T. Pagler, and N. Wang HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis Cell Metab. 7 2008 365 375
24. U. Tchoua, W. D'Souza, N. Mukhamedova, D. Blum, E. Niesor, J. Mizrahi, C. Maugeais, and D. Sviridov The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport Cardiovasc. Res. 77 2008 732 739
25. H. Tanigawa, J.T. Billheimer, J. Tohyama, Y. Zhang, G. Rothblat, and D.J. Rader Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport Circulation 116 2007 1267 1273
26. R.J. Schmidt, T.P. Beyer, W.R. Bensch, Y.W. Qian, A. Lin, M. Kowala, W.E. Alborn, R.J. Konrad, and G. Cao Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo Biochem. Biophys. Res. Commun. 370 2008 634 640
27. L.G. Fong, E. Bonney, J.C. Kosek, and A.D. Cooper Immunohistochemical localization of low density lipoprotein receptors in adrenal gland, liver, and intestine J. Clin. Invest. 84 1989 847 856
28. C. Le May, S. Kourimate, C. Langhi, M. Chetiveaux, A. Jarry, C. Comera, X. Collet, F. Kuipers, M. Krempf, B. Cariou, and P. Costet Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia Arterioscler. Thromb. Vasc. Biol. 29 2009 684 690
29. F. Lalanne, G. Lambert, M.J. Amar, M. Chetiveaux, Y. Zair, A.L. Jarnoux, K. Ouguerram, J. Friburg, N.G. Seidah, H.B. Brewer Jr., M. Krempf, and P. Costet Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells J. Lipid Res. 46 2005 1312 1319
30. S. Rashid, D.E. Curtis, R. Garuti, N.N. Anderson, Y. Bashmakov, Y.K. Ho, R.E. Hammer, Y.A. Moon, and J.D. Horton Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 Proc. Natl. Acad. Sci. USA 102 2005 5374 5379
31. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J. Am. Coll. Cardiol. 59 2012 2344 2353
32. E.A. Stein, S. Mellis, G.D. Yancopoulos, N. Stahl, D. Logan, W.B. Smith, E. Lisbon, M. Gutierrez, C. Webb, R. Wu, Y. Du, T. Kranz, E. Gasparino, and G.D. Swergold Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N. Engl. J. Med. 366 2012 1108 1118